Pohl A - Search Results

1

Pharmacogenomics and -genetics in colorectal cancer.

Pohl A, Lurje G, Manegold PC, Lenz HJ. Pohl A, et al. Adv Drug Deliv Rev. 2009 May 20;61(5):375-80. doi: 10.1016/j.addr.2008.10.002. Epub 2008 Dec 3. Adv Drug Deliv Rev. 2009. PMID: 19100300 Review.

2

Targeting metastatic colorectal cancer in 2008: a long way from 5-FU.

Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz HJ. Pohl A, et al. Oncology (Williston Park). 2008 Apr 15;22(4):456-62; discussion 462-3, 467-8, 474 passim. Oncology (Williston Park). 2008. PMID: 18472617 Free article. Review.

3

Stem cells in colon cancer.

Pohl A, Lurje G, Kahn M, Lenz HJ. Pohl A, et al. Clin Colorectal Cancer. 2008 Mar;7(2):92-8. doi: 10.3816/CCC.2008.n.012. Clin Colorectal Cancer. 2008. PMID: 18501067 Review.

4

Individualization of therapy for colorectal cancer based on clinical and molecular parameters.

Pohl A, Lenz HJ. Pohl A, et al. Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S38-41. Gastrointest Cancer Res. 2008. PMID: 19343148 Free PMC article.

5

Thymidylate synthase gene variations: predictive and prognostic markers.

Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. Lurje G, et al. Among authors: pohl a. Mol Cancer Ther. 2009 May;8(5):1000-7. doi: 10.1158/1535-7163.MCT-08-0219. Epub 2009 Apr 21. Mol Cancer Ther. 2009. PMID: 19383851 Review.

6

Gender disparities in metastatic colorectal cancer survival.

Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. Hendifar A, et al. Among authors: pohl a. Clin Cancer Res. 2009 Oct 15;15(20):6391-7. doi: 10.1158/1078-0432.CCR-09-0877. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789331 Free PMC article.

7

Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).

Zhang W, Azuma M, Lurje G, Gordon MA, Yang D, Pohl A, Ning Y, Bohanes P, Gerger A, Winder T, Hollywood E, Danenberg KD, Saltz L, Lenz HJ. Zhang W, et al. Among authors: pohl a. Anticancer Res. 2010 Oct;30(10):4209-17. Anticancer Res. 2010. PMID: 21036743 Clinical Trial.

8

Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.

Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Lurje G, et al. Among authors: pohl a. Pharmacogenet Genomics. 2008 Feb;18(2):161-8. doi: 10.1097/FPC.0b013e3282f4aea6. Pharmacogenet Genomics. 2008. PMID: 18192902

9

Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer.

Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ. Lurje G, et al. Among authors: pohl a. Pharmacogenet Genomics. 2009 Feb;19(2):95-102. doi: 10.1097/FPC.0b013e32831a9ad1. Pharmacogenet Genomics. 2009. PMID: 18987561

10

Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus.

Lurje G, Leers JM, Pohl A, Oezcelik A, Zhang W, Ayazi S, Winder T, Ning Y, Yang D, Klipfel NE, Chandrasoma P, Hagen JA, DeMeester SR, DeMeester TR, Lenz HJ. Lurje G, et al. Among authors: pohl a. Ann Surg. 2010 May;251(5):857-64. doi: 10.1097/SLA.0b013e3181c97fcf. Ann Surg. 2010. PMID: 20101173

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

300 results

Search Page